HC Andersen Capital Events 15/3: Meet the management in Zerion Pharma and NeoDynamics
HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.
Zerion Pharma - A disruptive solution for poor drug solubility
Meet Zerion Pharma’s management – CEO Ole Wiborg who will run through the investment proposal and business case. Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round.
The company aims to make a real difference in health care with its Dispersome™ technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market, and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome technology makes it possible to reduce the amount of active drugs in a given product by 75%. OBS. This event will be held in Danish.
Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Claus Thestrup 13.01 02/03-2023.
The 15th of March at 1:00 - 1:30 PM
Register here.
NeoDynamics - Management elaborates on options for long-term financing
Meet CEO Anna Eriksrud and CFO Aaron Wong who will elaborate on options to raise long-term capital to enable the commercialization of NeoNavia in the US.
The Board of Directors and Management of NeoDynamics are currently exploring various options to raise long-term capital to enable the commercialization and execution of the Company’s US strategy, following the FDA clearance received in September 2022 for NeoDynamic’s innovative pulse biopsy system NeoNavia®. Funding proceeds will also be used to support the Company’s continued expansion and operations in Europe. These options for raising long-term capital include debt financing, a potential dual stock exchange listing to expand the Company’s shareholder base, as well as issues of new shares, warrants and/or convertible instruments.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 10.46 AM 10/03-2023.
The 15th of March at 2:00 - 2:30 PM
Register here.
Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
HC Andersen Capital digitializes the relation between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial markets.